ArticleDrugs in R&D2021

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.

Aneal Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.